DAXOR CORP 10-Q Summary: Period Ended September 30, 1999
Business Context and Reporting Period
This Form 10-Q covers the quarterly and nine-month periods ended September 30, 1999, for DAXOR Corporation. The company operates in the medical technology sector, specifically focusing on blood banking, semen banking, and the development of a Blood Volume Analyzer. The company recently received licenses for its blood and semen bank operations in February 1999 and is actively marketing its Blood Volume Analyzer through a "reagent loaner plan."
Key Financial Metrics
| Metric | Nine Months Ended Sep 30, 1999 | Nine Months Ended Sep 30, 1998 |
|---|---|---|
| Total Revenues | $2,248,424 | $2,088,320 |
| Operating Revenues | $433,557 | $259,303 |
| Dividend Income | $1,387,542 | $1,475,648 |
| Net Income (Loss) | $154,552 | $(181,018) |
| Net Income Per Share | $0.03 | $(0.04) |
| Cash and Equivalents (End of Period) | $24,676 | $89,683 |
| Marketable Securities (Fair Value) | $37,985,527 | $43,016,243 |
| Total Assets | $38,959,394 | $44,056,349 |
| Total Liabilities | $7,151,595 | $8,752,515 |
| Shareholders' Equity | $31,807,799 | $35,303,834 |
| Loans Payable | $2,099,199 | $2,050,549 |
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net income of $154,552 for the nine months ended September 1999, reversing a net loss of $181,018 in the same period in 1998.
- Revenue Composition: Operating revenues increased significantly by approximately 67% ($174,254 increase), driven by the licensing of blood and semen bank operations. Conversely, dividend income decreased by roughly 6% ($88,106 decrease).
- Expense Reduction: Net interest expense dropped dramatically from $447,464 in 1998 to $99,837 in 1999, contributing heavily to the improved bottom line.
- Investment Portfolio: The fair value of marketable securities declined from $43.0 million to $38.0 million, resulting in a reduction of net unrealized holding gains included in equity.
- Cash Flow: Operating activities consumed $303,841 in cash, an improvement over the $623,952 cash outflow in the prior year. Investing activities provided $789,288 in cash, primarily from the sale of investments.
Outlook, Risks, and Management Commentary
- Strategic Focus: Management plans to focus financial reserves on developing and marketing the Blood Volume Analyzer. The company anticipates this product will become a major income source.
- Marketing Strategy: The "reagent loaner plan" is being utilized to market the Blood Volume Analyzer. While this strategy offers greater long-term profit potential, it generates slower initial income compared to direct equipment sales.
- Liquidity and Capital Needs: The company currently has adequate resources for initial marketing and sustaining blood/semen banking operations. However, management notes that a nationwide expansion of blood banking or a dominant shift to the reagent loaner model for the Analyzer may require additional capital.
- Risks: The company's liquidity is heavily dependent on its marketable securities portfolio, which is pledged as collateral for loans totaling approximately $2.1 million. A significant decline in the value of these securities could impact leverage ratios and borrowing capacity.
Investor Verification Checklist
- Revenue Sustainability: Verify the growth trajectory of operating revenues now that the blood and semen banks are fully licensed, distinguishing this from investment income.
- Portfolio Valuation: Assess the stability of the $38 million marketable securities portfolio, which constitutes the vast majority of total assets and serves as collateral for debt.
- Product Adoption: Monitor the adoption rate of the Blood Volume Analyzer under the reagent loaner plan to determine if it meets the projected timeline for becoming a major revenue driver.
- Cash Burn Rate: Review the cash flow from operations, which remains negative, to ensure the company can sustain operations without diluting shareholders or increasing debt significantly.